MedPath

Aimmune Therapeutics, Inc.

Aimmune Therapeutics, Inc. logo
🇺🇸United States
Ownership
Public, Subsidiary
Established
2011-01-01
Employees
275
Market Cap
-
Website
http://www.aimmune.com

Clinical Trials

51

Active:38
Completed:10

Trial Phases

3 Phases

Phase 1:38
Phase 2:3
Phase 3:10

Drug Approvals

2

FDA:2

Drug Approvals

Zenpep

Approval Date
Feb 28, 2024
FDA

VOWST

Approval Date
Apr 21, 2023
FDA

Clinical Trials

Distribution across different clinical trial phases (51 trials with phase data)• Click on a phase to view related trials

Phase 1
38 (74.5%)
Phase 3
10 (19.6%)
Phase 2
3 (5.9%)

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

Phase 2
Terminated
Conditions
Hen Egg Allergy
First Posted Date
2019-08-14
Last Posted Date
2022-03-10
Lead Sponsor
Aimmune Therapeutics, Inc.
Target Recruit Count
15
Registration Number
NCT04056299
Locations
🇺🇸

Arkansas Children's Hospital, Little Rock, Arkansas, United States

🇺🇸

Peninsula Research Associates, Rolling Hills Estates, California, United States

🇺🇸

Allergy & Asthma Medical Group and Research Center, A.P.C, San Diego, California, United States

and more 8 locations

Peanut Oral Immunotherapy Study of Early Intervention for Desensitization

Phase 3
Completed
Conditions
Peanut Allergy
First Posted Date
2018-11-09
Last Posted Date
2023-03-02
Lead Sponsor
Aimmune Therapeutics, Inc.
Target Recruit Count
146
Registration Number
NCT03736447
Locations
🇺🇸

Arkansas Children's Hospital, Little Rock, Arkansas, United States

🇺🇸

Sean N. Parker Center for Allergy & Asthma Reseach, LPCH at El Camino Hospital, Mountain View, California, United States

🇺🇸

Peninsula Research Associates, Inc., Rolling Hills Estates, California, United States

and more 20 locations

Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents

Phase 3
Terminated
Conditions
Peanut Allergy
First Posted Date
2018-10-12
Last Posted Date
2021-07-13
Lead Sponsor
Aimmune Therapeutics, Inc.
Target Recruit Count
1
Registration Number
NCT03703791
Locations
🇪🇸

Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain

🇪🇸

Corporacio Sanitaria Parc Tauli, Sabadell, Barcelona, Spain

🇪🇸

Hospital Universitario Severo Ochoa, Leganes, Madrid, Spain

and more 8 locations

AR101 Real-World Open-Label Extension Study

Phase 3
Completed
Conditions
Peanut Allergy
First Posted Date
2017-11-09
Last Posted Date
2021-11-02
Lead Sponsor
Aimmune Therapeutics, Inc.
Target Recruit Count
243
Registration Number
NCT03337542
Locations
🇺🇸

Clinical Research Center of Alabama, Birmingham, Alabama, United States

🇺🇸

Medical Research of Arizona, Scottsdale, Arizona, United States

🇺🇸

Banner University of Arizona Medical Center, Tucson, Arizona, United States

and more 57 locations

Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)

Phase 3
Completed
Conditions
Peanut Allergy
Interventions
First Posted Date
2017-09-25
Last Posted Date
2024-12-19
Lead Sponsor
Aimmune Therapeutics, Inc.
Target Recruit Count
911
Registration Number
NCT03292484
Locations
🇺🇸

Alabama Allergy and Asthma Center, Birmingham, Alabama, United States

🇺🇸

Medical Research of Arizona, Allergy, Asthma & Immunology Associates, Scottsdale, Arizona, United States

🇺🇸

Banner Univ. of Arizona Medical Center, Tucson, Arizona, United States

and more 90 locations
  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.